GVR Report cover Base Editing Market Size, Share & Trends Report

Base Editing Market Size, Share & Trends Analysis Report By Product & Services (Platform, gRNA Design), By Application (Drug Discovery & DevelopmentAgriculture, Veterinary), By Type, By End-u-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report ID: GVR-4-68040-335-0
  • Number of Report Pages: 120
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2023
  • Forecast Period: 2024 - 2030 
  • Industry: Healthcare

Base Editing Market Size & Trends

The global base editing market size was estimated at USD 271.80 million in 2023 and is projected to grow at a CAGR of 14.6% from 2024 to 2030. Rising prevalence of chronic & rare diseases, increased application of genomic research in therapeutics, and increased government funding & growing focus on genomic studies are the factors driving the market.

Base Editing market size and growth rate, 2024 - 2030

Base editing (BE), a CRISPR-Cas9 genome editing technology, offers potential therapeutic strategies against diseases. Base editing has shown significant potential in correcting genetic mutations associated with immunodeficiency disorders and chronic diseases such as cardiovascular disorders, metabolic conditions, and certain types of cancer. Moreover, base editing sensor libraries enable high-throughput screening and functional analysis of cancer-associated single nucleotide variants. The rising number of cancer cases worldwide elevates the demand for novel therapeutics. For instance, in 2022, cancer was one of the leading causes of death worldwide, with 20 million new cases and 9.7 million deaths, according to the National Cancer Institute. By 2040, it is projected that cancer cases will reach 29.9 million, with 15.3 million cancer-related deaths.

Furthermore, the increasing research in gene therapy based on base editing technology presents significant opportunities for market growth. For instance, according to an article published in January 2023, a base-edited target CAR-T cell therapy was carried out in clinical trials on a young girl with leukemia. This trial showed positive results, which cured her disease.

Recent advancements in base editing technology have shown significant progress in crop genetic improvement. For instance, according to a study published in Genome Biology in February 2024, scientists have developed highly efficient base editors for cotton plants. The GhABE8e base editor exhibited 99.9% editing efficiency compared to GhABE7.10, which had 64.9% efficiency, with no off-target editing detected. Such studies provide an important technical platform and genetic information for studying and creating ideal plant architecture.

The COVID-19 pandemic has led to a surge in demand for advanced genetic tools and technologies for various applications, including precision medicine and gene therapies to treat chronic and infectious diseases. However, the pandemic has led to multiple disruptions in research and development activities, the supply chain, and market funding scenarios. Moreover, companies are entering strategic collaborations that could accelerate growth post-pandemic. For instance, in May 2023, AstraZeneca signed a license agreement with Revvity to gain access to Revvity’s Pin-point gene editing platform.

Market Concentration & Characteristics

The development of advanced genome editing tools has revolutionized therapeutic development and disease detection by enabling easier genomic DNA manipulation. Numerous industry players have introduced technologically advanced and innovative products as a result.

The market is also characterized by a moderate level of merger and acquisition activities undertaken by several industry players. This is due to several factors, including the desire to gain a competitive advantage in the industry and the need to consolidate in a rapidly growing market. In October 2023, Eli Lilly and Company acquired opt-in rights from Beam Therapeutics for Verve Therapeutics’ four base editing programs focused on three cardiovascular disease targets.

Base Editing Market Concentration & Characteristics

The development and application of base editing technologies are subject to stringent regulations to ensure safety, efficacy, and ethical considerations. Ethical considerations play a significant role in regulating base editing technologies. Many countries have bioethical committees or advisory boards assessing the ethical implications of gene-editing tools like base editors. 

The industry has seen significant growth in recent years, driven by the increasing demand for base editing technology due to the growing research & development activities in the genomics area. Moreover, companies are entering research and development deals, leveraging their gene editing technologies against various therapeutic targets. For instance, an agreement was signed between Novo Nordisk and Life Edit Therapeutics in May 2023, thereby elevating Novo Nordisk’s gene editing technologies.

The industry is experiencing moderate regional expansion, driven by an increasing customer base for base editing products and services. In addition, companies are entering into license agreements to access new market regions. In October 2020, Merck signed a licensing agreement with Canada-based PanCELLa and U.S.-based Takara Bio for its CRISPR genome editing technology.

Products & Services Insights

The product segment dominated the market in terms of revenue in 2023 and is anticipated to grow at the highest CAGR of 15.3%. The product segment is further categorized into platform, kits & reagents, plasmid, and base editing libraries. Base editing platforms are tools used in genetic engineering to make precise changes to the DNA of living organisms. These platforms typically consist of a base editor enzyme, guide RNA (gRNA), and a delivery system. The base editor enzyme is designed to target specific nucleotides within the DNA sequence, allowing for the conversion of one base pair to another without causing double-strand breaks. This technology offers a more targeted approach than traditional gene editing methods like CRISPR-Cas9, reducing off-target effects and increasing efficiency. Furthermore, kits and reagents customized for base editing applications provide researchers with the essential tools to accurately and safely modify specific genes using CRISPR-based technologies. These kits usually include essential components such as Cas9 proteins, gRNAs, deaminase enzymes, and other materials necessary for precise base editing in various systems. Moreover, base editing plasmids are essential tools in genetic engineering, specifically for precise nucleotide changes at targeted genomic loci without the need for double-stranded breaks.

Based on services, the segment is further categorized into gRNA design and cell line engineering. Base editing services allow customers to generate point mutations in DNA. These services utilize CRISPR-based editing technologies that allow for the direct conversion of DNA bases without inducing double-strand breaks. The design of guide RNAs (gRNAs) is crucial for base editing processes. gRNAs direct the modified Cas9 enzyme to specific locations in the genome for base editing. The development of software tools has significantly advanced the field of CRISPR-based editing.  They simplify the process of designing targeting guide RNAs for single or multiple targets on variant or reference genomes across different organisms and plants.

Application Insights

The drug discovery & development segment dominated the market and accounted for a 52.08% share in 2023. In addition, this segment is anticipated to grow at the highest CAGR of 15.0% from 2024 to 2030. Base editing technology has significant potential in drug discovery and development due to its ability to precisely modify single nucleotides in the genome without causing double-strand breaks. This precision makes base editing an essential tool for correcting genetic mutations associated with various diseases, including those targeted by pharmaceutical interventions. Furthermore, base editing can create disease models for drug screening and testing. Using base editors, researchers can mimic genetic conditions associated with certain diseases by introducing specific mutations into cellular or animal models. The base editing technology is a helpful tool for optimizing drug targets and pathways by precisely modifying gene expression or protein function. Researchers can utilize base editors to adjust specific nucleotides involved in drug targets, regulatory elements, or signaling pathways, thus improving therapeutic outcomes.

Base editing enables precise genome editing and has created new opportunities for crop improvement in plant breeding. Over the past few years, this technology has been used to edit the genomes of various plant species such as rice, maize, cotton, oilseed rape, tomato, strawberry, and watermelon. Furthermore, base editing technologies, specifically cytosine base editors (CBEs), have shown significant potential for precise genome editing in pigs, which are important animals for both agricultural and biomedical purposes. Base editing approaches have implications for creating genetic modifications that can lead to desirable traits or model human diseases in pigs.

Type Insights

The DNA base editing segment held the largest market share in 2023 and is expected to grow at the highest CAGR of 15.4% over the forecast period. DNA base editing is a technique used in genome editing to modify single nucleotides within the DNA of living cells precisely. This technology allows researchers to introduce specific point mutations without causing double-strand breaks in the DNA, providing a more targeted approach than traditional gene-editing methods such as CRISPR-Cas9. Moreover, DNA base editing allows researchers to study the impact of specific genetic mutations on cellular functions, creates accurate disease models for studying pathogenesis & testing potential therapies, and helps correct genetic mutations underlying various diseases.

RNA base editing is an emerging technology that allows precise modifications to RNA molecules. It offers a reversible and temporary method to correct disease-causing mutations without the risk of permanent genotoxic effects. This approach has gained significant attention recently due to its potential applications in treating genetic disorders and advancing therapeutic interventions. Moreover, as research in this field continues to advance, the potential for using RNA base editing in clinical settings to treat a variety of genetic disorders remains promising.

End-use Insights

Pharmaceutical and biotechnology companies dominated the market, with the largest revenue share of 51.40% in 2023. These companies are actively exploring base editing as a tool to develop novel therapies. They are leveraging base editing technology to address various genetic disorders and advance the field of precision medicine. They are investing more in research and development to utilize advanced gene editing tools to create new treatments for various diseases. These companies aim to develop curative therapies and enhance patient outcomes by combining precise base editing with CRISPR's gene-targeting capabilities.

Base Editing market share and size, 2023

The academic and research institutes segment is anticipated to grow at the highest CAGR over the forecast period. Base editing technology has gained significant traction in academic and research institutes due to its precise genome editing capabilities. Academic and research institutions utilize base editing tools like CRISPR for a wide range of applications, including the study of functional genomics, disease research, crop improvement, model organism studies, etc. Moreover, extensive ongoing research in drug discovery & therapeutics further contributes to market growth. For instance, according to research published in Science Magazine in March 2023, David Liu’s gene editing lab got promising results in alleviating spinal muscular atrophy (SMA) using base editing technology in mouse models.

Regional Insights

North America dominated the market and accounted for a 40.26% share in 2023, attributed to the region’s advanced healthcare infrastructure, strong presence of leading biotechnology firms, and significant funding for genomic research. Furthermore, growing healthcare expenditure, increasing awareness of genetic therapies, and supportive government initiatives are expected to boost the market. 

Base Editing Market Trends, by Region, 2024 - 2030

U.S. Base Editing Market Trends

The base editing market in the U.S. is anticipated to grow over the forecast period due to increasing government funding & growing focus on genomic studies and the rising prevalence of diseases. Moreover, increasing research in drug discovery, personalized medicine, and targeted therapies is further anticipated to fuel market growth.

Europe Base Editing Market Trends

The base editing market in Europe is anticipated to grow over the forecast period. Europe has been actively involved in genomic studies and research, contributing to its growth in the region. Moreover, as more companies invest in research and development, focusing on applications such as disease treatment, animal model development, and crop improvement breeding, further propels market growth.

The UK base editing market is expected to grow over the forecast period due to increasing R&D expenditures by pharmaceutical and biotechnology companies, which focus on molecular biology research for gene therapy and drug discovery and development. Furthermore, government laws regarding genetically modified crops will likely boost the base editing market. For instance, in March 2023, the Government of England legalized the commercial production of gene-edited food. Thus, using base editing technology, scientists can enhance agricultural outcomes & food production.

The base editing market in Germany is expected to grow over the forecast period due to the growing incidence and prevalence of genetic disorders,favorable government policies supporting research activities, and key players' introduction of new drugs and therapies.

France base editing market is expected to grow over the forecast period due to the rising prevalence of genetic and metabolic disorders. To cure such disorders, several researchers are using genome editing technologies. In addition, France is making several efforts to promote innovation in plant genetics, which is expected to increase market growth. PlantAlliance is a public-private consortium consisting of 31 partners who are involved in developing innovative agroecological cropping systems using gene editing technology.

Asia Pacific Base Editing Market Trends

The base editing marketinAsia Pacific is expected to experience rapid growth, with a projected CAGR of 15.60% from 2024 to 2030. This is attributed to the increasing incidence of chronic diseases, growing government support for genomics research and development, and a rising preference for gene editing technologies in agriculture and therapeutics.

China base editing market is anticipated to grow over the forecast period. Researchers in China are currently using base editing technology for a wide range of applications, from agriculture to medicine. In May 2024, China approved producing and consuming gene-edited wheat after maize and soybean. Such approvals expedite the use of gene editing technology, thereby boosting market growth.

The base editing market in Japan is expected to witness rapid growth over the forecast period. The market has seen significant developments with the approval and commercialization of genome-edited food products. Genome-edited fish and tomatoes are already being grown by aquaculture operators and farmers. Such approvals and commercialization of food products by genome editing technologies signify a shift towards more efficient and sustainable agricultural practices while meeting consumer demands for novel and improved food products.

India base editing market is anticipated to grow rapidly over the forecast period due to an intense demand for genome editing technology to improve agriculture productivity suitably. The National Agri-Food Biotechnology Institute, part of the Department of Biotechnology (DBT), uses CRISPR technology to modify bananas in the country. In addition, ongoing research projects on CRISPR/Cas9 by Indian researchers and scientists are anticipated to boost the Indian base editing market.

Middle East & Africa Base Editing Market Trends

The base editing market in the Middle East and Africais poised to grow in the near future, as increasing applications of biotechnology in healthcare and agriculture are contributing to its expansion.

Saudi Arabia base editing market is expected to grow over the forecast period due to increasing investments in healthcare innovation and research. The country’s focus on advancing biotechnology and genomics, coupled with the rising awareness of genetic drugs and personalized medicine, is driving the expansion of the base editing market in Saudi Arabia.

The base editing market in Kuwait is anticipated to witness growth over the forecast period owing to the escalating investment in scientific research and development by both governmental and private entities. This investment is propelling advancements in genetic technologies, consequently presenting opportunities for developing novel and enhanced genome editing tools and techniques.

Key Base Editing Company Insights

Key players operating in the base editing market are undertaking various initiatives to strengthen their market presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships play a key role in propelling market growth.

Key Base Editing Companies:

The following are the leading companies in the base editing market. These companies collectively hold the largest market share and dictate industry trends.

  • ElevateBio
  • Merck KGaA
  • Revvity
  • Maravai LifeSciences
  • GenScript
  • Beam Therapeutics
  • Intellia Therapeutics, Inc.
  • Cellectis
  • ElevateBio
  • Creative Biogene
  • Bio Palette Co., Ltd

Recent Developments

  • In September 2023, Revvity introduced Pin-point base editing reagents, enhancing accessibility to gene editing platforms for preclinical and clinical trials and drug discovery and development researchers.

  • In September 2023, ARCH Venture Partners financed AIRNA with USD 30 million to advance AIRNA’s pipeline of RNA editing therapeutics.

  • In March 2019, Beam Therapeutics received USD 135 million in Series B funding to expedite its next-generation CRISPR technologies and expand its pipeline of base editing platforms.

Base Editing Market Report Scope

Report Attribute


Market size value in 2024

USD 300.27 million

Revenue forecast in 2030

USD 681.24 million

Growth rate

CAGR of 14.6% from 2024 to 2030

Actual data

2018 - 2023

Forecast period

2024 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2024 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product & services, application, type, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Mexico; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

ElevateBio; Merck KGaA; Revvity; Maravai LifeSciences; GenScript; Beam Therapeutics; Intellia Therapeutics, Inc.; Cellectis; ElevateBio; Creative Biogene; Bio Palette Co., Ltd.

Customization scope

Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options


Global Base Editing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 - 2030. For this study, Grand View Research has segmented the global base editing market report based on product & services, application, type, end-use, and region.

  • Products & Services Outlook (Revenue, USD Million, 2018 - 2030­)

    • Product

      • Platform

      • Kits & Reagents

      • Plasmids

      • Base Editing Libraries

    • Services

      • gRNA Design

      • Cell Line Engineering

  • Application Outlook (Revenue, USD Million, 2018 - 2030)

    • Drug Discovery & Development

    • Agriculture

    • Veterinary

  • Type Outlook (Revenue, USD Million, 2018 - 2030)

    • DNA Base Editing

    • RNA Base Editing

  • End-use Outlook (Revenue, USD Million, 2018 - 2030)

    • Academic & Research Institutes

    • Contract Research Organizations

    • Pharmaceutical & Biotechnology Companies

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

      • Mexico

    • Europe

      • UK

      • Germany

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

      • South Korea

      • Thailand

    • Latin America

      • Brazil

      • Argentina

    • MEA

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.